Kornimate/medical-research-clean huggingface dataset:
study to investigate if embody's retinol gummies improve the early signs of skin aging and overall skin health

Conditions: Acne, Adult

Summary: the embody retinol study is a single-arm clinical trial on skin aging prevention and adult acne. the purpose of this study is to determine the effect of a retinol gummy in adults aged 18-45 on skin aging and overall skin health.

embody has developed a retinol gummy with the aim to improve the appearance of early signs of aging, such as fine lines, dark spots, and sagging. embody's retinol gummy has also the goal to reduce the overall frequency of adult acne and an improvement of overall skin health by promoting hydrated, brightened skin. the study aims to collect self-reported outcomes and photographic images to understand the assessment of the efficacy of treatment from the participant's perspective, and if participants see an improvement in their fine lines, wrinkles, dark spots, and sagging.

Eligibility criteria:
inclusion criteria: * male or female between 18-45 years old * must be in good general health * may experiences adult acne and/or early-stage wrinkles that are not treated by topical or oral prescription drugs/medication * must maintain a basic skincare routine * must discontinue the use of other dietary supplements * must be willing to comply with the requirements of the protocol * is able to communicate in english * is willing to skip their normal skincare routine * must provide written informed consent form (icf) * is willing and able to share feedback and take skin pictures via the used technology portal exclusion criteria: * unwilling to provide consent * unwilling to skip their normal skincare routine * unwilling to follow the routine of the protocol * use of other oral retinoids * use of prescription medication relevant to the skin * undergoing any cosmetic procedures during the study including botox, laser or chemical treatments * deep-set of wrinkles * history of the following medical conditions or diseases: * kidney disease * liver disease * alcohol abuse * use of prescription drug (topical or oral) that is targeted at any sort of skin condition (for example retinoids) * any known allergies/sensitivities to nuts

Keywords: skin aging adult acne
a study to evaluate the efficacy and safety of cjc-1134-pc in patients with type 2 diabetes mellitus who are currently on metformin monotherapy

Conditions: Type 2 Diabetes Mellitus

Summary: this is a multicenter, randomized, placebo-controlled, double-blind, phase ii study. the objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with cjc-1134-pc in patients with type 2 diabetes mellitus who are currently on metformin monotherapy.


Eligibility criteria:
major inclusion criteria: * bmi: 27 to 45 kg/m2 * stable type 2 diabetes mellitus for at least 3 months, as defined by the investigator * stable life-style, i.e. diet \& physical activity, as determined by the investigator * stable metformin daily dose ≥1000 mg for at least 3 months * glycosylated hemoglobin (hba1c) at screening ≥ 7.1% and ≤ 11%

Keywords: type 2 diabetes mellitus, incretins, glp-1, hba1c, metformin
caffeinol hypothermia protocol

Conditions: Acute Ischemic Stroke

Summary: caffeinol is a combination of caffeine and alcohol. the amount given is about the same as 1-2 glasses of wine and 3-4 cups of coffee. the patient receives a one time dose given over two hour while being cooled to 34.5 c.


Eligibility criteria:
inclusion criteria: 1. age 18-80 years 2. clinical presentation of acute ischemic stroke 3. computed tomography (ct) scan compatible with acute ischemic stroke. 4. time to caffeinol treatment \< 240 minutes from stroke onset. 5. time to hypothermia initiation \< 300 minutes from stroke onset. 6. presumed cortical location of stroke (must have at least on sign such as aphasia, neglect, visual field cut) 7. national institutes of health stroke scale (nihss) \> 8 at time of each treatment. 8. tissue plasminogen activator (tpa) treated patients must meet all established criteria for tpa. exclusion criteria: 1. etiology other than ischemic stroke. 2. item 1a on nihss \> 1 3. signs/symptoms of subcortical, brainstem or cerebellar stroke. 4. symptoms resolving or nihss \< 8 at time of each treatment. 5. nihss \> 20 if right hemisphere or \>25 if left hemisphere 6. known alcoholic 7. clinical or laboratory evidence of alcohol intoxication. 8. historical evidence of exogenous caffeine exposure beyond daily consumption of coffee or soft drinks. 9. known hematologic dyscrasias that affect thrombosis. 10. comorbid conditions likely to complicate therapy: 1. end-stage cardiomyopathy 2. uncompensated or clinically significant arrhythmia 3. myopathy 4. liver disease 5. history of pelvic or abdominal mass likely to compress inferior vena cava. 6. end-stage aids 7. history of clinically significant gastrointestinal (gi) bleeding 8. impaired renal function with creatinine clearance, 50 ml/min 11. intracerebral / intraventricular hemorrhage 12. systolic blood pressure (sbp) \> 210 or \ 100 or \< 50 mmhg 13. severe coagulopathy 14. pregnancy 15. use of monoamine oxidase inhibitor (maoi),serotonin-specific reuptake inhibitor (ssri) or tricyclic antidepressants (tca) within the preceding 2 weeks 16. known history of epilepsy.

Keywords: stroke nonhemorrhagic hypothermia
lithium disilicate crowns study

Conditions: Caries; Dental Trauma

Summary: cad-cam crowns made of lithium disilicate are placed in patients by using either a dual-curing adhesive or a self-adhesive luting material in combination with total etch/universal bonding agent.


Eligibility criteria:
inclusion criteria: * patients will be at least 18 years of age, of either gender, and of any ethnic background. * each patient should have at least one carious lesion or defective restoration to be restored on a maxillary or mandibular premolar or molar tooth. * each lesion or defective restoration should exhibit sufficient size or loss of tooth structure requiring a full crown restoration. * the tooth should have at least one opposing tooth in occlusion and one adjacent tooth with an intact proximal contact. * all teeth will test vital and be asymptomatic at the beginning of treatment. no more than two restorations will be placed per patient. exclusion criteria: * devital or sensitive teeth * teeth with prior endodontic treatment of any kind * teeth with a history of direct or indirect pulp capping procedures * patients with significant untreated dental disease to include periodontitis and/or rampant caries * women who self-report that they are possibly pregnant, pregnant, or lactating, as elective dental treatment is not indicated at these times * patients with a self-reported past history of allergies to the materials to be used in the study including composite resin cements or ceramic restorative materials * patients unable to return for the recall appointments
outcomes of a novel technique of mini- incision and self-express (mise) for breast abscess

Conditions: Breast Infection

Summary: conventional techniques for treatment of breast abscess, such as incision and drainage/percutaneous drainage, have disadvantages. bedside mini-incision and self-express (mise) is a novel technique for breast abscess. the outcomes of mise were compared to the conventional techniques.

outcomes such as recovery time, duration of antibiotics use etc will be compared between the various groups of intervention.

Eligibility criteria:
inclusion criteria: * patients with a pathologically confirmed breast abscess and * presenting at kk women's and children's hospital, singapore exclusion criteria: patients with: * mastitis * granulomatous mastitis * breast fillers with infection * ruptured abscess prior to intervention * other interventions or bilateral breast infection
developing a risk assessment system of multidrug-resistant organisms infection

Conditions: Bacterial Infections

Summary: 1. a retrospective analysis was performed to determine the prevalence of multidrug- resistant organisms infection in icu from october 2017 to october 2019. 2. non-mdro patients were selected by random sampling in a ratio of 1:1 to the final mdro group during the same period , and select the risk factors of infection with multi-drug resistant bacteria by comparing the two groups. 3. randomly select 30% of the sample size as the validation set, and the remaining 70% for the training set to establish a model. using multi-factor logistic regression, decision tree classification, artificial neural network, support vector machine, bayesian network method to establish risk assessment system for multidrug-resistant organisms infection respectively.using validation set data to calculate the area under the roc curve (auc) and sensitivity, specificity of models and comparing the prediction accuracy of several models. finally, choose a more suitable risk assessment system for multidrug-resistant organisms infection. 4. predict the patient's infection risk level according to the best risk assessment system and develop a low-to-high intervention plan.


Eligibility criteria:
inclusion criteria： * duration of icu admission ≥ 48h * no less than 18 years old exclusion criteria: * patients with mdro infection at the time of admission * lack of case data * mdro colonized patients

Keywords: risk assessment system multidrug-resistant organisms icu
medical follow-up of new cases of polyarthritis in children and young adults

Conditions: Juvenile Idiopathic Arthritis; Rheumatoid Arthritis; Psoriatic Arthritis; Systemic Lupus Erythematosus; Diffuse Systemic Sclerosis; Seronegative Arthritis

Summary: population: juvenile idiopathic arthritis (jia), rheumatoid arthritis (ra) and seronegative / psoriatic / undifferentiated arthritis (ua), systemic lupus erythematosus (sle) or diffuse systemic sclerosis dss). naïve to basic treatment or treated for ≤ 3 months; except for patients with jia. these 5 cohorts will be subject to standardized clinical monitoring.

this study is proposed by the rheumatology and pediatrics departments of the 3 french-speaking universities. the first objective will be to include a progressive number of new young patients (≤ 50 years) in order to optimize and standardize care and clinical response objectives. the number of 25% of new incident cases will be sought with an increase of 20% each year during the 5 to 10 years of this project. population: jia, ra/ua, sle, dss (american congres of rheumatology criteria). naïve to basic treatment or treated for ≤ 3 months; except for patients with jia. these 5 cohorts will be subject to standardized clinical monitoring and specific objectives that will make it possible to analyze the number of patients with a good control of the disease and/or a clinical remission, defined according to the international criteria.

Eligibility criteria:
inclusion criteria: * diagnosis of juvenile idiopathic arthritis, rheumatoid arthritis and seronegative / psoriatic / undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis (acr criteria). * naïve to basic treatment or treated for ≤ 3 months; except for patients with jia. exclusion criteria: * treated for \> 3 months * \> 50 years old
transfemoral versus transradial partial splenic artery embolization in patients with hypersplenism

Conditions: Hypersplenism

Summary: the present study aimes at comparing the transradial and transfemoral approaches for partial splenic embolization in patients with hypersplenism.

since its development in 1979, partial splenic embolization (pse) has been universally accepted to treat patients with hypersplenism in preference to surgical splenectomy. the spleen is the primary source of antibodies, lymphocyte production, and responsible for phagocytosis of white cells. additionally, it plays an essential role in the immune system. unlike splenectomy, partial splenic embolization (pse) maintained partial splenic function and was thought to be an effective alternative to treat thrombocytopenia and leukopenia resulted from hypersplenism with fewer complications. pse is usually performed using a femoral artery approach that requires bed rest for a few hours. recently, the transradial approach, with less obvious need for bed rest, has been more widely applied for cardiovascular intervention.

Eligibility criteria:
inclusion criteria: 1. patients with hypersplenism and severe thrombocytopenia (platelet count \< 50,000/mm3). 2. the functional status of the liver should be child a or early b according to child-pugh classification (5-7 points) (albumin ≥ 2.8 g/dl, bilirubin ≤ 3 mg/dl, prothrombin time ≤ 4 or inr \< 1.7, no ascites, no encephalopathy). 3. eligible for both femoral and radial puncture. exclusion criteria: 1. patients referred for embolization as treatment of traumatic splenic injury. 2. patients lost during follow-up.
decoding the genetic landscape of skeletal diseases

Conditions: Genetic Skeletal Diseases; Skeletal Dysplasia; Molecular Causes; Skeletal Disorder

Summary: this 5-year project aims to (1) search for genetic causes for yet unsolved congenital skeletal disorders (gsds); (2) study consequences of the newly identified pathogenic variants in cells and in transgenic mice, (3) summarize data on natural course and complications for different gsd groups. for patients with unsolved gsd, the investigators search for molecular causes of gsds using whole genome sequencing (wgs) and total ribonucleic acid (rna) sequencing. candidate gene variants are selected using genome or transcriptome sequencing data, clinical findings and screening of omics databases. causality of the new variants is studied in cells and in transgenic mice models. molecular and clinical findings are summarized for different gsd groups.

genetic skeletal disorders (gsds) are a large group of rare diseases caused by abnormalities in genes regulating skeletal development. this 5-year project aims to (1) search for genetic causes for yet unsolved congenital skeletal disorders; (2) study consequences of the newly identified pathogenic variants in cells and in transgenic mice, (3) summarize data on natural course and complications for different gsd groups. the project is a collaboration between the dept of clinical genetics, karolinska university hospital, lab of clinical genetics and lab of bone and cartilage physiology, karolinska institutet and sahlgrenska academy. in a well-characterized group of 300 gsd participants whose dna samples were analyzed using whole genome sequencing (wgs), there are 120 study participants with unsolved diagnoses. for those participants, we search for molecular causes of gsds using wgs and total rna sequencing. candidate gene variants are selected using genome or transcriptome sequencing data, clinical findings and screening of omics databases. causality of the new variants is studied in cells and in transgenic mice models. molecular and clinical findings are summarized for different gsd groups. our results improve diagnostics for gsds, advance knowledge on pathogenesis and help establishing new individual follow-up and treatment strategies for patients with gsds. this project increases understanding of skeletal pathophysiology and will contribute to the development of novel treatment methods for skeletal diseases.

Eligibility criteria:
inclusion criteria: clinically suspected skeletal dysplasia based on previous investigations abnormal height radiographic abnormalities of the skeleton in addition to other syndromic features healthy relatives of the affected study participants exclusion criteria: no radiographic data available from clinical investigations suspected environmental or multifactorial causes
study of a suprachoroidal retinal prosthesis

Conditions: Retinitis Pigmentosa; Choroideremia

Summary: this study is a proof of principal, to evaluate a safety and efficacy of a prototype suprachoroidal retinal implant.

retinal visual prostheses are currently in early development as an intervention to improve functional vision in people who have become blind from retinal degenerative eye disease. this study follows on from an initial proof of concept study (n=3) between 2012 and 2014, and will test a second-generation retinal prosthesis device, which has the ability to be used outside of the laboratory environment (i.e. is fully implantable).

Eligibility criteria:
inclusion criteria: * aged 18 years or older * either gender * a confirmed history of outer retinal degenerative disease such as retinitis pigmentosa or choroideremia * remaining visual acuity of bare light perception or less in both eyes * functional inner retina (ganglion cells and optic nerve), as shown by the ability to perceive light and/or a measurable corneal electrically evoked visual response * a history of at least 10 years of useful form vision in the worse seeing eye exclusion criteria: * optic nerve disease (history of glaucoma of more than 1 month, or history of any other optic neuropathy) * diseases of the inner retina including, but not limited to, central retinal artery or vein occlusion (crao, crvo), end stage diabetic retinopathy, retinal detachment, traumatic retinal damage, infectious retinal disease, inflammatory retinal disease. * inability to visualise the retina due to corneal or other ocular media opacities (corneal degenerations, dense cataracts, trauma, lid malpositions) * any ocular condition that predisposes the participant to rubbing their eyes * cognitive deficiencies, including dementia or progressive neurological disease * psychiatric disorders, including depression, as diagnosed by a qualified psychologist * deafness or significant hearing loss * inability to speak or understand english * pregnancy * presence of a cochlear implant * participant enrolled in another investigational drug or device trial for the treatment of their ocular condition * poor general health, which would exclude them from obtaining a general anaesthetic * unrealistic expectations of the investigational device to provide functional vision * poorly controlled diabetes * epilepsy * unsuitable level of regular nystagmus (which would prevent ocular images from being obtained) * anyone with medical devices (implanted or carried) that could cause serious health problems if compromised by electro-magnetic interference
continuation study of lapatinib monotherapy or lapatinib in combination with other anti-cancer agents

Conditions: Neoplasms, Breast

Summary: this study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase i trial that has met its study objectives.


Eligibility criteria:
inclusion criteria: * participation in a phase i lapatinib trial that has met its study objectives. * ability to understand and provide written informed consent to participate in this study. * male or female greater than or equal to 18 years of age. * a female subject is eligible to participate if she is of: * non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or post-menopausal defined as 12 months of spontaneous amenorrhea. females on hormone replacement therapy (hrt) and whose menopausal status is in doubt will be required to use one of the contraception methods stated in the protocol if they wish to continue their hrt during the study. otherwise, they must discontinue hrt to allow confirmation of post-menopausal status prior to study enrollment. for most forms of hrt, at least two to four weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of hrt. following confirmation of their post-menopausal status, they can resume use of hrt during the study without use of a contraceptive method. * child-bearing potential, has a negative serum pregnancy test at baseline, and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. female subjects must agree to use contraception from two weeks prior to the administration of study drug and throughout the entire active study treatment period until four weeks after the last dose of study medication. exclusion criteria: * permanent discontinuation of lapatinib in the previous study due to intolerance or treatment failure. * is a pregnant or lactating female. * is considered medically unfit for the study by the investigator as a result of the medical interview, physical exam, or baseline investigations. * currently receiving treatment with any medications listed on the prohibited medication listed in the protocol * has class iii or iv heart failure as defined by the new york heart association (nyha) functional classification system. * have current active hepatic or biliary disease (with exception of subjects with gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).

Keywords: cancer lapatinib combination therapy chronic administration
a study of ak104 in subjects with unresectable locally advanced nsclc

Conditions: NSCLC (Non-small Cell Lung Cancer)

Summary: this study compares the efficacy and safety of ak104 versus sugemalimab as consolidation therapy in patients with unresectable, locally advanced nsclc who have not progressed following concurrent or sequential chemoradiotherapy.


Eligibility criteria:
inclusion criteria: 1. subjects must sign the written informed consent form (icf) voluntarily. 2. age ≥18 years. 3. histologically or cytologically confirmed unresectable locally advanced (stage iii) nsclc. 4. absence of known egfr sensitive mutations and negative for alk and ros1 fusions. 5. concurrent or sequential chemoradiotherapy completed 1 to 42 days prior to the first dose. 6. chemotherapy regimens should be in accordance with current clinical guidelines. 7. consolidation chemotherapy is not allowed after radiotherapy. 8. total dose of radiotherapy is 60gy±10% (54gy-66gy). 9. no disease progression after concurrent or sequential chemoradiotherapy. 10. ecog performance status score of 0-1. 11. expected survival of over 3 months. 12. adequate organ and bone marrow function. exclusion criteria: 1. the histopathology contains any component of small cell lung cancer. 2. currently participating in another interventional clinical study. 3. previously received immunotherapy, biotherapy, anti-angiogenic drugs, or small molecule targeted drugs. 4. patients with clinically significant cardio-cerebrovascular or venous thromboembolic diseases. 5. prior malignancy active within the previous 3 years except for the locally curable cancers that have been apparently cured. 6. tumor invades important vessels or organs. 7. experienced acute exacerbation of chronic obstructive pulmonary disease or asthma within 4 weeks prior to the first dose. 8. presence of interstitial lung disease that requires treatment. 9. toxicities of prior anticancer therapy have not resolved to ≤ grade 1 (nci-ctcae version 5.0). 10. experienced severe infection within 4 weeks prior to the first dose. 11. underwent major surgery or experienced severe trauma within 4 weeks prior to the first dose. 12. any condition that required systemic treatment with corticosteroids (\> 10 mg daily prednisone or equivalent) or other immunosuppressive agents within 14 days prior to the first dose. 13. active autoimmune diseases or history of autoimmune diseases that may relapse. 14. previous history of severe hypersensitivity reactions to other monoclonal antibodies. 15. previous organ transplantation or allogeneic hematopoietic stem cell transplantation.